Morningstar's Fair Value for SpaceX (SPCX) Stock Is $62. The Stock Trades at $157. One of Them Is Wrong by $1.2 Trillion.

SpaceX is described as trading at a 152% premium to Morningstar’s fair value estimate, with a $154 share price versus $62 fair value and a $2.05 trillion market cap. The article highlights a 78x price-to-sales ratio, nearly $5 billion in 2025 losses, and a 22.6% decline over the past week, arguing the stock is richly valued despite long-term growth potential. Starlink remains profitable, but slowing growth and shrinking revenue per user add to the cautionary view.

Analysis

This note is less about one private name and more about the valuation pressure it creates across the late-stage space. When a marquee asset trades at a premium that implies perfection, it resets the hurdle rate for every adjacent private growth company: secondary sellers get more aggressive, new rounds clear at lower marks, and crossover funds have a cleaner excuse to rotate toward profitable public comps. The second-order effect is that the cost of capital for capital-intensive frontier tech rises just as the sector needs repeated funding to sustain growth.

The most important catalyst path is not day-to-day price action but a financing/operating mismatch over the next 2-4 quarters. If margin dilution persists while growth decelerates, the market will stop treating the business like a platform monopoly and start treating it like an expensive infrastructure build with execution risk. That tends to compress multiples fastest when the broader market weakens, because investors will not pay peak revenue multiples for an asset with negative earnings and slowing monetization.

On the public side, the cleaner expression is not long/short the private name directly but to own the beneficiaries of capital reallocation. Highly profitable AI/semicap leaders can absorb incremental allocation as investors search for growth with actual cash generation; that supports NVDA and MU relative to speculative private-tech exposure. NFLX is more of a sentiment barometer than a direct beneficiary, but if growth capital rotates away from moonshot platforms, subscription cash-flow compounders should see relatively better multiple support.

The contrarian view is that the headline premium may be partially justified if the company remains the cheapest path to owning a scarce strategic asset with embedded optionality. But the market is already paying for that optionality many years in advance, so the burden of proof shifts to sustained monetization and operating leverage. Until there is evidence of that, the risk/reward is asymmetric to the downside, especially if growth stocks de-rate broadly.

Key Decisions for Investors

• Avoid initiating new exposure to the private name into the next earnings print; if already involved, reduce size into strength and reassess only after guidance, because the next catalyst is likely to be multiple compression rather than fundamental re-rating.
• Pair trade: long NVDA / short a basket of unprofitable late-stage growth proxies over a 3-6 month horizon; the trade benefits if capital keeps rotating toward cash-generative AI leaders and away from duration-heavy story stocks.
• Long MU as a relative-value beneficiary of AI infrastructure spend, funded against higher-beta growth exposure; if the market rewards earnings power over narrative, MU’s cash return profile should hold up better in a risk-off tape.
• Consider a small hedged position in NFLX only as a defensive growth sleeve; it is not the cleanest beneficiary, but its recurring cash flow makes it a better parking place than speculative private-market exposure if sentiment turns.
• For venture/secondary exposure, tighten liquidity assumptions and mark down private holdings with similar revenue profiles over the next 1-2 quarters; this premium can bleed into comps faster than most allocators expect.